RECOVERY · Injectable
TB-500 + BPC-157 Combo.
The Wolverine Stack — complete healing protocol
How it works
Class & mechanism.
In short
The BPC-157 + TB-500 combination — nicknamed the 'Wolverine Stack' — pairs two tissue-repair peptides with complementary mechanisms. BPC-157 may drive new blood vessel growth, while TB-500 may help cells migrate to injury sites. It is studied for complex musculoskeletal recovery where both blood supply and cell movement matter — though evidence for the combination is preclinical and anecdotal.
Class
Synthetic Peptide Stack
Mechanism
BPC-157 and TB-500 operate through distinct but convergent repair pathways, making their combination mechanistically complementary rather than redundant. BPC-157 drives angiogenesis via VEGFR2/FAK-paxillin signaling, upregulates growth hormone receptor expression in fibroblasts, and stabilizes the nitric oxide system for vascular protection. TB-500 works upstream through actin sequestration, mobilising stem and progenitor cells to injury sites and upregulating TGF-β and FGF-2. Together, BPC-157 handles the vascular infrastructure (new blood supply to injured tissue) while TB-500 handles cellular logistics (recruiting the right cells to the right place). The combination addresses two of the three core bottlenecks in tissue repair simultaneously: blood supply and cell migration.
Personalized Peptides provides DNA-driven peptide recommendations — we are not a compounding pharmacy, peptide synthesis company, or clinical provider.
Did you know
The combination is nicknamed the 'Wolverine Stack' in biohacker and athletic communities — named after Marvel's famously self-healing mutant — because the two peptides together cover so many independent repair pathways that users describe injury timelines that seem implausibly fast compared to conventional recovery.
Benefits
What it does.
Synergistic tissue repair across multiple injury types — the complementary pathways suggest the stack may outperform either peptide alone for complex musculoskeletal injuries (tendons, ligaments, muscle, bone), though this has not been confirmed in controlled human trials
Faster return to function post-surgery — may address both the vascular repair phase (BPC-157) and the cellular remodeling phase (TB-500) in parallel rather than sequentially
Gut health and systemic healing combined — BPC-157 contributes gastrointestinal and mucosal repair activity that TB-500 lacks, which may make the combo relevant for those with gut compromise alongside physical injuries
Broad anti-inflammatory coverage — both peptides may modulate inflammation through different mechanisms, potentially reducing the risk of one pathway being insufficient for complex or chronic inflammatory states
Neurological and cardiovascular support — BPC-157's preclinical neuroprotective and gut-brain axis activity may combine with TB-500's cardiac repair potential for broader systemic recovery in post-surgical or high-stress contexts
The science
Peer-reviewed findings.
Research supporting this compound's mechanisms and safety profile.
What this does not mean
The BPC-157 + TB-500 stack consists of research chemicals. The information on this page is educational and does not constitute medical advice, diagnosis, or treatment. Neither BPC-157 nor TB-500 is FDA-approved for treating injuries, post-surgical recovery, or any other use. This page does not recommend, endorse, or prescribe any compound for human use. Always consult a qualified healthcare provider before making health decisions. Personalized Peptides provides DNA-driven educational context and test interpretation — not clinical protocols or pharmaceutical recommendations.
Both BPC-157 and TB-500 demonstrate convergent effects on angiogenesis promotion and inflammatory modulation while maintaining distinct molecular targets — a preclinical rationale for synergistic therapeutic applications in regenerative medicine contexts
SOURCE · GlobalRPh Clinical Review: BPC-157 and TB-500 Background, Indications, Efficacy, and Safety (2025)
BPC-157 shows stronger activity in gastrointestinal and connective tissue repair models, while Thymosin Beta-4 (TB-500's parent compound) demonstrates distinct cardiac and immunological effects — the stack covers tissue types that neither covers alone
SOURCE · Newtropin.com Comparative Clinical Overview; Raw Amino comparative research review
The 'Wolverine Stack' (BPC-157 + TB-500) has generated significant interest in regenerative medicine specifically because of its biologically complementary rationale: BPC-157 targets the extracellular matrix and vascular signaling while TB-500 targets intracellular actin dynamics and cell mobilization — two non-overlapping mechanisms
SOURCE · Medical Spa Rx: The Wolverine Stack Explained (2024)
Protocol
How to use it.
Dosing
BPC-157: 250–500 mcg daily via subcutaneous injection. TB-500: 2–4 mg twice weekly during the loading phase. Both are administered separately (never combined in the same vial — stability concerns). Typical protocol: inject BPC-157 daily near injury site; inject TB-500 2–3x weekly subcutaneously into abdomen or near injury. Total weekly TB-500 load is typically 4–6 mg during the first 4–6 weeks. PK data for individual components: see the BPC-157 and TB-500 product pages for preclinical pharmacokinetic rationale on each peptide. Neither BPC-157 nor TB-500 has published human PK studies — dosing is empirically derived — but the rationale panels detail what is known about absorption, distribution, and clearance for each.
Cycle
Loading phase: 4–6 weeks at full dose (both peptides). Maintenance phase: reduce TB-500 to 2 mg/week, continue BPC-157 at 250 mcg/day for a further 4–8 weeks. Rest period of 4–8 weeks between cycles. For acute post-surgical recovery, a single 8–12 week combined cycle is common clinical practice.
Contraindications
When to skip it.
Neither peptide is FDA-approved for human therapeutic use. Both are banned by WADA. Never combine in the same syringe or vial. Theoretical cancer risk applies to both (angiogenesis promotion) — mandatory cancer screening before initiating. Use under physician supervision only. Not for use during active cancer treatment.
Always cleared with your concierge before protocol start.
Regulatory Context
FDA compounding status.
| FDA Status | Risk Level | Compounding | Key Date |
|---|---|---|---|
| PCAC Review July 2026 | 🔴 At Risk | Awaiting PCAC — 503A eligibility review (both components) | PCAC July 23, 2026 |
Wolverine Stack. Both BPC-157 and TB-500 under PCAC review July 23. Regulatory posture tracks the most restrictive component (BPC-157).
Source: FDA Federal Register, PCAC agendas, industry analyses. Educational context only — not legal advice. Review after July 23-24, 2026 PCAC meeting.
Pricing
What it costs.
Indicative range for TB-500 + BPC-157 Combo, sourced from vetted US and EU dispensing suppliers. Concierge confirms the exact figure once your match is locked.
Indicative range (USD)
Sourced through vetted dispensing partners in the United States and European Union. Concierge confirms the exact figure once your match is locked.
- 0199% purity verified, third-party tested
- 02Includes vial and reconstitution guidance
- 03Concierge supplier match included with every protocol
See TB-500 + BPC-157 Combo pricing — and your supplier match.
Pricing is unlocked once we know who you are. Take the 3-minute quiz and we'll match you to a US or EU dispensary based on your location and protocol fit.
- Live USD price range
- US & EU supplier shortlist
- Concierge sign-off on dosing
Indicative price range: $136–$204 USD